title: Diffuse choroidal hemangioma associated with exudative retinal detachment in a Sturge-Weber syndrome case: photodynamic therapy and intravitreous bevacizumab.
abstract: We report the case of a young female patient with a diffuse choroidal hemangioma (DCH) and glaucoma as part of Sturge-Weber syndrome (SWS) and symptomatic retinal detachment that was treated successfully with photodynamic therapy (PDT) and intravitreal bevacizumab (IVB). The patient was treated with a single session of PDT, a 689-nm laser was used to deliver 50J/cm(2) with a maximum spot size of 6400μm, for 166s. IVB was administered 3 days later. The exudative retinal detachment (ERD), macular edema and visual acuity improved one week after treatment. The patient was followed for 18 months with no recurrence of ERD, and her visual acuity was preserved. PDT followed by IVB may be an effective treatment option for visual deterioration due to ERD in patients with DCHs, as are found in SWS.
authors.affiliation: Instituto Mexicano del Seguro Social, Unidad Médica de Alta Especialidad No. 71, Ophthalmology Deparment, Torreón, Coahuila, Mexico. Electronic address: ejanayap@hotmail.com.
authors.forename: Edwin J
authors.initials: EJ
authors.lastname: Anaya-Pava
authors.affiliation: Instituto Mexicano del Seguro Social, Unidad Médica de Alta Especialidad No. 71, Ophthalmology Deparment, Torreón, Coahuila, Mexico; Fundación Oftalmológica de la Laguna, Retina Service, Torreón, Coahuila, Mexico.
authors.forename: Carlos H
authors.initials: CH
authors.lastname: Saenz-Bocanegra
authors.affiliation: Instituto Mexicano del Seguro Social, Unidad Médica de Alta Especialidad No. 71, Ophthalmology Deparment, Torreón, Coahuila, Mexico.
authors.forename: Alejandro
authors.initials: A
authors.lastname: Flores-Trejo
authors.affiliation: Instituto Mexicano del Seguro Social, Unidad Médica de Alta Especialidad No. 71, Ophthalmology Deparment, Torreón, Coahuila, Mexico.
authors.forename: Norma A
authors.initials: NA
authors.lastname: Castro-Santana
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000068258:Bevacizumab / Q000008:administration & dosage*; D002830:Choroid Neoplasms / Q000188:drug therapy*; D003131:Combined Modality Therapy / Q000379:methods; D005260:Female; D006391:Hemangioma / Q000188:drug therapy*; D006801:Humans; D058449:Intravitreal Injections; D010778:Photochemotherapy / Q000379:methods*; D017319:Photosensitizing Agents / Q000627:therapeutic use; D011166:Porphyrins / Q000008:administration & dosage; D012163:Retinal Detachment / Q000188:drug therapy*; D013341:Sturge-Weber Syndrome / Q000188:drug therapy*; D016896:Treatment Outcome; D000077362:Verteporfin; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin; D000068258:Bevacizumab
keywords: Choroidal hemangioma; Photodynamic therapy; Sturge–Weber syndrome; Vascular endothelial growth factor